Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Cizzle Biotechnology Holdings PLC ( (GB:CIZ) ) just unveiled an update.
Cizzle Biotechnology Holdings PLC has launched a new corporate website to enhance communication with stakeholders, including shareholders, investors, and customers. This development is part of the company’s strategy to support its growth and facilitate the global launch of its CIZ1B Biomarker test for early-stage lung cancer. The website aims to provide a user-friendly interface and will be updated with new content as the company finalizes its regulatory and launch plans in the USA.
More about Cizzle Biotechnology Holdings PLC
Cizzle Biotechnology Holdings PLC is a UK-based diagnostics developer focused on creating early cancer tests. The company has developed the CIZ1B biomarker into a non-invasive, cost-effective blood test for early detection of lung cancer. They have entered into commercial royalty-bearing arrangements and collaborations with cancer care centers. Cizzle was listed on the Main Market of the London Stock Exchange in May 2021.
Average Trading Volume: 840,912
Technical Sentiment Signal: Strong Buy
Current Market Cap: £6.14M
See more insights into CIZ stock on TipRanks’ Stock Analysis page.